Baxdrostat Aldosterone Synthase Inhibition for Resistant Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antihypertensive medications are ineffective for treating resistant hypertension, leading to increased risks of cardiovascular and renal diseases due to chronically elevated blood pressures, necessitating a novel medication that can lower blood pressure effectively.
Innovation Solution
Administering (R)-Compound 1, also known as baxdrostat, a specific aldosterone synthase inhibitor, to patients with resistant hypertension, either alone or in combination with other antihypertensive agents, to reduce blood pressure levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antihypertensive medications are used, then blood pressure control is achieved in most patients, but they are ineffective for treating resistant hypertension
Solution Approach 1:
The patent introduces a novel mechanism of action by inhibiting aldosterone synthase, representing a fundamental parameter change from conventional antihypertensive mechanisms. This new pharmacological parameter (aldosterone synthase inhibition) provides efficacy in resistant hypertension where conventional parameters have failed
Solution Approach 2:
The patent segments the hypertension treatment approach by specifically targeting the aldosterone pathway with baxdrostat, separating this mechanism from conventional antihypertensive classes. This segmentation allows specialized treatment for the resistant hypertension subgroup without compromising standard therapy for other patients
2Object-affected harmful factors
If blood pressure is not controlled in resistant hypertension, then cardiovascular and renal disease risks increase, but effective treatment options are limited
Solution Approach 1:
The patent introduces baxdrostat as an intermediary substance that specifically blocks aldosterone synthase, preventing aldosterone production. This intermediary mechanism addresses the underlying hormonal dysfunction in resistant hypertension, thereby reducing cardiovascular and renal disease risks where direct conventional therapies have failed
Solution Approach 2:
By introducing aldosterone synthase inhibition as a new therapeutic parameter, the patent expands the available treatment toolkit for resistant hypertension, directly addressing the limited effectiveness of current options in this high-risk population
Data Source
AI summary
The disclosure provides methods of treating hypertension in a subject in need thereof, comprising administering baxdrostat.